Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions
Divij Mathew(Parker Institute for Cancer Immunotherapy), E. John Wherry(Parker Institute for Cancer Immunotherapy), Eileen C. Goodwin(University of Pennsylvania), Claudia P. Arevalo(University of Pennsylvania), Jennifer E. Wu(Parker Institute for Cancer Immunotherapy), Michael R. Betts(University of Pennsylvania), C.A.G. Ittner(University of Pennsylvania), Nicholas Han(Translational Therapeutics (United States)), Kito Nzingha(Translational Therapeutics (United States)), Sigrid Gouma(University of Pennsylvania), Ariel R. Weisman(University of Pennsylvania), Scott E. Hensley(University of Pennsylvania), Yinghui Huang(Translational Therapeutics (United States)), Marcus J. Bolton(University of Pennsylvania), Nuala J. Meyer(Translational Therapeutics (United States)), Simon F. Lacey(University of Pennsylvania), Cécile Alanio(Inserm), Derek A. Oldridge(California University of Pennsylvania), Laura A. Vella(Children's Hospital of Philadelphia), Justin Kim, Jeanette Dougherty(Translational Therapeutics (United States)), M. Betina Pampena(University of Pennsylvania), Allison R. Greenplate(California University of Pennsylvania), Josephine R. Giles(Parker Institute for Cancer Immunotherapy), Oliva Kuthuru(Translational Therapeutics (United States)), Amy E. Baxter(Translational Therapeutics (United States)), Alexander C. Huang(University of Pennsylvania), Elizabeth M. Anderson, Leticia Kuri-Cervantes(University of Pennsylvania), Sokratis A. Apostolidis(University of Pennsylvania), Sasikanth Manne(Translational Therapeutics (United States)), Kurt D’Andrea(University of Pennsylvania), Zeyu Chen(Kingmed Diagnostics), Chen Fang(University of Pennsylvania), Madison E. Weirick(University of Pennsylvania), John P. Reilly(University of Pennsylvania), Ajinkya Pattekar(University of Pennsylvania)
Cited by 115
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
T cell responses in patients with COVID-19
|Nature reviews. Immunology|2020|873